1887
Surveillance and outbreak report Open Access
Like 0

Abstract

From 6 September 2015–May 2016, a large mumps outbreak occurred among vaccinated students in Norway. A case was defined as a person presenting with a clinical mumps infection, notified between 1 September 2015 and 30 June 2016. Confirmed cases had positive laboratory confirmation and probable cases had an epidemiological link; PCR-positive specimens were genotyped. A total of 232 cases were notified (230 confirmed) with median age of 23 years (range 4–81) and 61% were male. Of 68 (30%) confirmed cases that were genotyped, 66 were genotype G and associated with the outbreak. Cases that had received two doses of the measles-mumps-rubella (MMR) vaccine had reduced risk of hospitalisation (adjusted relative risk (aRR): 0.14; 95%CI: 0.03–0.57), mumps-related orchitis (aRR: 0.21; 95% CI: 0.08–0.55) and severe outcome (aRR: 0.25; 95% CI: 0.10–0.62) compared with those unvaccinated. A third dose of the vaccine was offered to approximately 1,300 fully vaccinated close contacts and subsequently reported cases decreased. This large outbreak, occurring among predominately vaccinated students, suggests the current genotype A vaccine offers suboptimal protection against mumps genotype G. We recommend maintaining high vaccination coverage and offering the vaccine to all unvaccinated individuals.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2018.23.38.1700642
2018-09-20
2018-10-17
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2018.23.38.1700642
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/23/38/eurosurv-23-38-3.html?itemId=/content/10.2807/1560-7917.ES.2018.23.38.1700642&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51-60. PMID: 17304707 
  2. Barskey AE, Schulte C, Rosen JB, Handschur EF, Rausch-Phung E, Doll MK, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012;367(18):1704-13.  https://doi.org/10.1056/NEJMoa1202865  PMID: 23113481 
  3. Takla A, Wichmann O, Klinc C, Hautmann W, Rieck T, Koch J. Mumps epidemiology in Germany 2007-11. Euro Surveill. 2013;18(33):20557.  https://doi.org/10.2807/1560-7917.ES2013.18.33.20557  PMID: 23968877 
  4. Zamir CS, Schroeder H, Shoob H, Abramson N, Zentner G. Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases. Hum Vaccin Immunother. 2015;11(6):1413-7.  https://doi.org/10.1080/21645515.2015.1021522  PMID: 25874726 
  5. Centres for Disease Control and Prevention (CDC). Chapter 9: Mumps: VPD surveillance manual. 5th ed. Atlanta, GA: CDC; 2012. Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt09-mumps.pdf
  6. Norwegian Institute of Public Health (NIPH). Vaccine against measles, mumps and rubella (MMR). Oslo: FHI; 18 Apr 2016. Available from: https://www.fhi.no/en/id/vaccines/childhood-immunisation-programme/vaccines-in-CIP/vaccine-against-measles-mumps-rubella/
  7. Norwegian Institute of Public Health (NIPH). Kusma - veileder for helsepersonell. Oslo: FHI; 02 Feb 2018. Available from: https://www.fhi.no/nettpub/smittevernveilederen/sykdommer-a-a/kusma---veileder-for-helsepersonell/
  8. European Commission. Commission Regulation (EC). Official Journal of the European Union. L 170/31. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945&from=EN#page=31/
  9. Jin L, Örvell C, Myers R, Rota PA, Nakayama T, Forcic D, et al. Genomic diversity of mumps virus and global distribution of the 12 genotypes. Rev Med Virol. 2015;25(2):85-101.  https://doi.org/10.1002/rmv.1819  PMID: 25424978 
  10. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register--SYSVAK. Euro Surveill. 2012;17(16):20147. PMID: 22551462 
  11. Zipprich J, Murray EL, Winter K, Kong D, Harriman K, Preas C, et al. Mumps Outbreak on a University Campus-California, 2011. JAMA. 2013;309(7):650-3.  https://doi.org/10.1001/jama.2012.193374 
  12. Brockhoff HJ, Mollema L, Sonder GJ, Postema CA, van Binnendijk RS, Kohl RH, et al. Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine. 2010;28(17):2932-6.  https://doi.org/10.1016/j.vaccine.2010.02.020  PMID: 20188683 
  13. Gouma S, Sane J, Gijselaar D, Cremer J, Hahné S, Koopmans M, et al. Two major mumps genotype G variants dominated recent mumps outbreaks in the Netherlands (2009-2012). J Gen Virol. 2014;95(Pt_5):1074-82.  https://doi.org/http://dx.doi.org/ 10.1099/vir.0.062943-0  PMID: 24603524 
  14. Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JMH, et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358(15):1580-9.  https://doi.org/10.1056/NEJMoa0706589  PMID: 18403766 
  15. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis. 2008;47(11):1458-67.  https://doi.org/10.1086/591196  PMID: 18959494 
  16. Quinlisk MP. Mumps control today. J Infect Dis. 2010;202(5):655-6.  https://doi.org/10.1086/655395  PMID: 20662719 
  17. Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006. Emerg Infect Dis. 2011;17(4):661-7, quiz 766.  https://doi.org/10.3201/eid1704.101461  PMID: 21470456 
  18. Hahné S, Whelan J, van Binnendijk R, Swaan C, Fanoy E, Boot H, et al. Mumps vaccine effectiveness against orchitis. Emerg Infect Dis. 2012;18(1):191-3.  https://doi.org/10.3201/eid1801.111178  PMID: 22260843 
  19. Sane J, Gouma S, Koopmans M, de Melker H, Swaan C, van Binnendijk R, et al. Epidemic of mumps among vaccinated persons, The Netherlands, 2009-2012. Emerg Infect Dis. 2014;20(4):643-8.  https://doi.org/10.3201/eid2004.131681  PMID: 24655811 
  20. Gouma S, Hahné SJ, Gijselaar DB, Koopmans MP, van Binnendijk RS. Severity of mumps disease is related to MMR vaccination status and viral shedding. Vaccine. 2016;34(16):1868-73.  https://doi.org/10.1016/j.vaccine.2016.02.070  PMID: 26954106 
  21. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206(10):1542-8.  https://doi.org/10.1093/infdis/jis568  PMID: 22966129 
  22. Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46(8):1172-80.  https://doi.org/10.1086/529141  PMID: 18444852 
  23. Vygen S, Fischer A, Meurice L, Mounchetrou Njoya I, Gregoris M, Ndiaye B, et al. Waning immunity against mumps in vaccinated young adults, France 2013. Euro Surveill. 2016;21(10):30156.  https://doi.org/10.2807/1560-7917.ES.2016.21.10.30156  PMID: 26987576 
  24. Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012;130(6):e1567-74.  https://doi.org/10.1542/peds.2012-0177  PMID: 23129075 
  25. Fiebelkorn AP, Coleman LA, Belongia EA, Freeman SK, York D, Bi D, et al. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open Forum Infect Dis. 2014;1(3):ofu094.  https://doi.org/10.1093/ofid/ofu094  PMID: 25734162 
  26. Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010. Pediatr Infect Dis J. 2013;32(4):374-80.  https://doi.org/10.1097/INF.0b013e318279f593  PMID: 23099425 
  27. Nordbø SAS, Krokstad S, Christensen A, Borge KS, Sagvik E. Mumps outbreak among vaccinated students in Trondheim, Norway in 2015. Poster presented at European Society for Clinical Virology meeting, 14th–17th September 2016, Lisbon.
  28. Bitsko RH, Cortese MM, Dayan GH, Rota PA, Lowe L, Iversen SC, et al. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. J Clin Microbiol. 2008;46(3):1101-3.  https://doi.org/10.1128/JCM.01803-07  PMID: 18184850 
/content/10.2807/1560-7917.ES.2018.23.38.1700642
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error